Longitudinal changes in personalized platelet count metrics are good indicators of initial 3-year outcome in colorectal cancer

Table 2 Comparison of the different baseline complete blood count ratios by anamnestic and clinicopathological data

Grouping factor	LMR	NLR	HPR	RPR	PLR
Sex
Male	3.30 ± 2.22c	4.69 ± 3.94a	0.45 ± 0.21d	0.051 ± 0.020a	58.96 ± 30.01c
Female	3.90 ± 1.88	4.05 ± 3.14	0.38 ± 0.18	0.047 ± 0.025	66.87 ± 25.68
Location of the tumor[22]
Left-sided	3.64 ± 2.50	4.55 ± 3.48	0.43 ± 0.21d,1	0.049 ± 0.027	61.06 ± 32.31
Right-sided	3.34 ± 1.96	4.54 ± 3.09	0.35 ± 0.19	0.048 ± 0.020	67.49 ± 28.98
Rectum	3.64 ± 1.81	4.24 ± 4.21	0.47 ± 0.19d,2	0.050 ± 0.019	59.19 ± 22.49a,2
Multiplex	4.03 ± 1.42	2.69 ± 1.05	0.45 ± 0.17	0.056 ± 0.014	68.17 ± 32.28
AJCC stage[21]
I	4.12 ± 2.10b,3	3.42 ± 2.99	0.49 ± 0.22a,4	0.054 ± 0.026a,3	63.22 ± 26.54
II	3.47 ± 1.55	4.23 ± 3.13	0.43 ± 0.17	0.051 ± 0.018	61.18 ± 23.52
III	3.82 ± 2.53	3.82 ± 2.29	0.42 ± 0.18	0.049 ± 0.015	63.47 ± 25.45
IV	3.29 ± 2.11	5.21 ± 4.50	0.39 ± 0.22d,3	0.047 ± 0.027	62.60 ± 33.47
Regional lymph node metastasis
No	3.59 ± 1.78	4.17 ± 3.64	0.44 ± 0.20b	0.051 ± 0.021a	62.58 ± 25.96
Yes	3.52 ± 2.35	4.59 ± 3.57	0.40 ± 0.20	0.048 ± 0.023	62.38 ± 30.47
Distant metastasis
None	3.76 ± 2.14a,5	3.83 ± 2.71d,5	0.45 ± 0.19c,5	0.051 ± 0.020a,5	62.38 ± 24.59
At the time of diagnosis	3.29 ± 2.11	5.21 ± 4.51	0.39 ± 0.22	0.047 ± 0.027	62.69 ± 33.51
Later with the course of the disease	3.62 ± 1.80	4.23 ± 3.27	0.42 ± 0.17	0.049 ± 0.016	62.51 ± 26.06
Radiotherapy
None	3.48 ± 2.15a,6	4.55 ± 3.72a,6	0.40 ± 0.20a,6	0.048 ± 0.022	62.94 ± 29.18
Preoperative	3.73 ± 2.06	4.11 ± 3.67	0.53 ± 0.24d,7	0.055 ± 0.033	56.41 ± 23.60
Postoperative	4.29 ± 1.38	3.00 ± 1.43	0.48 ± 0.16	0.051 ± 0.015	61.32 ± 22.12
Both	4.17 ± 1.55	2.53 ± 0.94	0.52 ± 0.10	0.049 ± 0.010	87.02 ± 18.13
Chemotherapy
None	3.29 ± 1.89a,8	5.06 ± 5.01b,8	0.42 ± 0.23	0.050 ± 0.023	60.61 ± 33.77
Adjuvant	3.82 ± 2.30	3.86 ± 2.57	0.44 ± 0.18	0.050 ± 0.017	63.73 ± 24.96
Metastatic	3.57 ± 1.89	4.29 ± 2.77	0.40 ± 0.20	0.047 ± 0.026	63.14 ± 25.95
Usage of biological agents
No	3.52 ± 2.16	4.53 ± 3.87	0.42 ± 0.21	0.050 ± 0.025a	61.96 ± 28.46
Yes	3.67 ± 1.93	4.03 ± 2.66	0.41 ± 0.17	0.046 ± 0.014	64.16 ± 28.26
Usage of regorafenib/trifluridine-tipiracil
No	3.58 ± 2.12	4.38 ± 3.66	0.42 ± 0.21	0.049 ± 0.023a	62.96 ± 28.66
Yes	3.21 ± 1.66	4.67 ± 2.85	0.41 ± 0.17	0.045 ± 0.012	55.65 ± 23.33
Type 2 diabetes mellitus
No	3.58 ± 2.09	4.41 ± 3.70	0.42 ± 0.20	0.048 ± 0.019	63.62 ± 29.85
Yes	3.47 ± 2.13	4.41 ± 3.38	0.43 ± 0.21	0.052 ± 0.031	58.87 ± 23.31
History of major CV event
No	3.60 ± 2.19	4.44 ± 3.78	0.42 ± 0.20	0.048 ± 0.023a	62.68 ± 29.21
Yes	3.38 ± 1.67	4.24 ± 2.82	0.43 ± 0.23	0.053 ± 0.022	61.80 ± 24.86
History of cholecystectomy
No	3.49 ± 2.03a	4.50 ± 3.75a	0.42 ± 0.20	0.049 ± 0.020	61.81 ± 29.09
Yes	4.02 ± 2.47	3.78 ± 2.55	0.42 ± 0.21	0.052 ± 0.035	66.61 ± 23.76

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

^dP < 0.0001.

¹Right-sided vs left-sided tumors.

²Right-sided tumors vs rectal cancer.

³Stage I vs Stage IV.

⁴Stage I vs Stage III.

⁵None vs at the time of diagnosis.

⁶None vs postoperative radiotherapy.

⁷None vs preoperative radiotherapy.

⁸None vs adjuvant chemotherapy.

LMR: Lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio; HPR: Hemoglobin-to-platelet ratio; RPR: Red blood cell distribution width (RDW)-to-platelet ratio; PLR: Platelet-to-lymphocyte ratio; AJCC: American Joint Committee on Cancer; CV: Cardiovascular. Of the total 835 study subjects, 82.40%, 79.04%, 92.57%, and 79.76% of LMR, NLR, RPR, and PLR were only available for statistical analysis, respectively.